SystImmune Announced First Patient Dosed In Ph2/3 IZABRIGHT-Breast01 Trial Of Iza-Bren In Previously Untreated Triple Negative Breast Cancer; $250M Milestone Payment Triggered From Bristol Myers Squibb

Author: Benzinga Newsdesk | October 13, 2025 04:09am

SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs. This milestone triggered a one-time payment of $250 million by Bristol Myers Squibb (NYSE:BMY), pursuant to the 2023 collaboration and exclusive license agreement between SystImmune and Bristol Myers Squibb. SystImmune is further eligible to receive up to an additional $250 million in contingent near-term payments and additional payments of up to $7.1 billion contingent upon the achievement of certain development, regulatory and sales performance milestones.

Posted In: BMY